249 results about "Senescent cell" patented technology

The invention discloses a ginseng extract rich in rare saponins and preparation and anti-aging application thereof, and belongs to the technical field of oral beauty and skin care products, the ginseng extract is obtained by fermentation treatment of ginseng powder through phytobacterium plantarum, and the preservation number of the phytobacterium plantarum is GDMCC No.64374. The ginseng extract rich in rare saponin is fermented by specific plant lactobacillus, ginsenoside is efficiently converted into CK and F1, various natural plant components such as ginseng polysaccharide are reserved, and a specific synergistic effect is generated. Through verification, the prepared ginseng extract is high in bioavailability, can more effectively inhibit cell inflammation, and can more effectively recover the mitochondrial function of senescent cells and inhibit cell senescence. The preparation method provided by the invention is high in operability and easy to standardize and intellectualize. Compared with a traditional extraction and purification method, the adopted fermentation method is more environmentally friendly and efficient, and large-scale production can be achieved in industrial production.

Described herein are methods and compositions for use in treating, preventing or reversing aging or age-related diseases, disorders or conditions. Also, described herein are methods and compositions for selective killing of senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies, diseases and conditions. As disclosed herein are methods where senescent cell associated diseases and disorders may be treated or prevented (i.e., likelihood of occurrence or development is reduced) by administering the described compositions.

The invention provides a probe for cell senescence analysis and a preparation method and application thereof, and belongs to the technical field of cell detection. The invention discloses a probe for cell aging analysis. The probe comprises fusion protein formed by fibronectin RGD and fluorescent protein, the fibronectin RGD is a polypeptide fragment containing an amino acid sequence as shown in SEQ ID NO: 1. The probe is fixed on a solid-phase carrier and then co-incubated with cells to be detected, the condition of senescent cells can be analyzed and judged by detecting the intensity of a fluorescence signal, the purpose of rapid analysis is achieved, the analyzed cells can be recycled and then continuously cultured, the detection cost is low, and the probe is suitable for large-scale popularization and application in the market.

Provided is a novel pharmaceutical composition for treating or preventing an aging-related disease by utilizing selective removal of a senescent cell. A pharmaceutical composition comprising an anti-integrin α11 (ITGA11) antibody as an active ingredient is administered to a subject.

The invention discloses a senescent cell recognition system and method based on mitochondrial morphology. The system is a classification network, and the input data of the system is a distribution image of mitochondria in subcellular level cells, the distribution image of mitochondria in cells, the shape and / or number of mitochondria distributed at different positions in a three-dimensional structure for displaying cells, and preferably the shape and number of mitochondria distributed at different positions in the three-dimensional structure for displaying cells. According to the senescence cell recognition system based on the mitochondrial morphology, the senescence cells jointly show mitochondrial morphological changes including mitochondrial distribution, mitochondrial shapes and mitochondrial number changes, the senescence cell recognition method is easy to conduct through computer vision, good robustness is achieved, and the senescence cell recognition system based on the mitochondrial morphology is suitable for being applied to senescence cell recognition. Compared with other senescence cell identification methods based on cell nucleus morphological characteristics, the senescence cell identification method based on the general characteristics of the senescence cells has good universality for different cell types.

[Problem] To provide a novel ferroptosis-inducing drug, and in particular, to provide a ferroptosis induction promoter that can effectively promote the induction of ferroptosis even in a cell having ferroptosis resistance even in a ferroptosis-inducing environment (for example, cancer cells and senescent cells). [Solution] Provided is a ferroptosis induction promoter comprising a drug that can reduce lysosomal pH.

The present invention belongs to the technical field of gene therapy. Provided are a chimeric antigen receptor nanocomposite and a preparation method therefor and the use thereof in the preparation of an anti-aging drug. The provided chimeric antigen receptor nanocomposite comprises a chimeric antigen receptor DNA plasmid specifically recognizing senescent cells, a polymer coupled with a signal peptide, a free polymer and an antibody polymer targeting T cells, wherein the chimeric antigen receptor DNA plasmid, the polymer coupled with a signal peptide, the free polymer and the antibody polymer targeting T cells are sequentially mixed and incubated to form the chimeric antigen receptor nanocomposite. The chimeric antigen receptor nanocomposite can rapidly generate senescent cell-marked chimeric antigen T cells in vivo. The engineered T cells have the ability to specifically eliminate senescent cells in vivo, and can rapidly and durably eliminate senescent cells in vivo, which is irreplaceable and has wide application prospects.

The invention discloses a hair-fixing and hair-loss-preventing composition, application thereof and a hair-fixing and hair-loss-preventing product. The hair fixing and hair loss preventing composition comprises 17-type collagen, a plant extract and adenosine substances, wherein the plant extract comprises a cacumen biotae extract. On the basis of inhibiting 5alpha-reductase and resisting oxidation, the composition disclosed by the invention also has the effects of fixing hair and preventing hair loss by virtue of ways of relieving inflammatory response, activating hair papilla cells, maintaining health of the hair papilla cells, reducing hair follicle senescence cells and the like.

The invention discloses an anti-aging longevity and qi-boosting soup composition and its use, comprising the following raw materials or extracts of raw materials in parts by weight: 9-30 parts of Radix Pseudostellariae, 9-30 parts of Poria, 6-20 parts of Angelicae Sinensis, 6-20 parts of stir-fried Semen Ziziphi Spinosae, 6-15 parts of Radix Ophiopogonis, 3-15 parts of roasted Polygala Tenuifolia, 10-60 parts of Longan Meat, 10-30 parts of Radix Rehmanniae, 9-30 parts of Scrophulariae, 3-20 parts of Acorus Gramineus, 9-30 parts of Semen Platycladi, 15-30 parts of roasted Plastron Tortoise, 15-30 parts of calcined Dragon Bone, 6-30 parts of Lotus, and 3-60 parts of Licorice. The composition can inhibit the activity of aging markers β-galactosidase in cells and animals, the expression of P16 or P21, remove senescent cells, improve the antioxidant capacity of cells and animals, reduce the expression level of inflammatory factors in cells and animals, and has a significant anti-aging effect.

The invention discloses a hair-fixing and hair-loss-preventing composition, application thereof and a hair-fixing and hair-loss-preventing product. The hair-fixing and hair-loss-preventing composition comprises 17-type collagen, a plant extract and a peptide substance, wherein the plant extract comprises a cacumen biotae extract. On the basis of inhibiting 5alpha-reductase and resisting oxidation, the composition disclosed by the invention also has the effects of fixing hair and preventing hair loss by virtue of ways of relieving inflammatory response, activating hair papilla cells, maintaining health of the hair papilla cells, reducing hair follicle senescence cells and the like.

This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 μM and stimulatory activity at 100 μM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).

The invention discloses a fluorescent / photoacoustic dual-mode diagnosis and treatment probe for detection and photodynamic removal of senescent cells, a preparation method and application, the probe takes a sulfur-substituted hemicyanine dye as a parent structure, a novel bromo-glycoside ligand is covalently coupled, and a blue-green solid is obtained after gradient purification. The probe system shows a remarkable optical response characteristic on beta-galactosidase (beta-Gal) and ideal singlet oxygen (1O2) generation efficiency; an optical signal and a photodynamic therapy effect of the probe can be specifically activated by beta-galactosidase (beta-Gal) overexpressed in cancerous cells and senescent cells under a light excitation condition; the result is successfully verified in a palbociclib-induced senescence melanoma model. According to the probe disclosed by the invention, collaborative regulation and control of dual-mode visual monitoring and precise photodynamic therapy of beta-Gal enzyme activity are realized for the first time, a novel tool is provided for researching a molecular mechanism of cell aging and developing a diagnosis and treatment strategy of aging-related diseases, and the probe has a remarkable application value in the fields of anti-tumor treatment and degenerative diseases.

The invention relates to a repairing composition for reducing senescence cell cumulant and a preparation method and application thereof, and the repairing composition comprises the following components in parts by weight: 0.01-7.0 parts of probiotic pellets PDRN, 0.01-3.0 parts of microspheroidized PDRN, 0.01-10.0 parts of a ginseng root extract, 0.01-10.0 parts of red ginseng fermented vesicles, a thickening agent, functional components and water. Under a formula system of a thickening agent and functional components, the probiotic pellets PDRN, the microspheroidized PDRN, the ginseng root extract and the red ginseng fermented vesicles are added, and all the components have a synergistic effect, so that the composition can penetrate into skin to achieve the effect of accurately repairing mitochondrial dysfunction, can directly remove senescent cells, reduces the senescent cell cumulant in a body in multiple ways, and has a good effect on repairing mitochondrial dysfunction. Therefore, the prepared skin care composition can effectively delay skin aging.

Machine learning techniques of characterizing senescence in an immobilized patient cell are disclosed. The techniques include: obtaining a patient cell image; passing the patient cell image to a trained machine learning system, where the trained machine learning system is trained using a training corpus that includes a plurality of training cell images, where the plurality of training cell images include a plurality of images of normal cells and a plurality of images of cells with senescence; obtaining an output from the trained machine learning model in response to the passing, where the output is indicative of a senescence property of the patient cell, and where the senescence property is non-binary; and providing an indication of the senescence property of the patient cell based on the output.

The invention relates to a calcium homeostasis disruptor in combination with a selective Death Receptor 5 (DR5) agonist for use in a method of treating a patient suffering from a tumour. The invention further relates to a pharmaceutical composition, comprising a calcium homeostasis disruptor in combination with a selective Death Receptor 5 (DR5) agonist and, optionally, an inducer of senescence. The invention further relates to methods of treating a patient having a tumour, and to a calcium homeostasis disruptor in combination with a selective DR5 agonist, for use in a method of selectively killing senescent cells, including senescent cancer cells.

The invention discloses a ternary fusion polypeptide Col-TF-1 targeting senescence cells, a monoclonal antibody mAb SC-1 matched with the ternary fusion polypeptide Col-TF-1, an anti-aging composition containing the ternary fusion polypeptide Col-TF-1 and the monoclonal antibody mAb SC-1, and application of the ternary fusion polypeptide Col-TF-1 The fusion polypeptide is formed by connecting a targeting peptide for targeting a senescence cell surface uPAR receptor, a collagen active peptide for promoting collagen synthesis and an immunomodulatory peptide for activating NK cells in series through a flexible linker GGGGS, and the amino acid sequence is as shown in SEQ ID NO.1. The invention further discloses a preparation method of the fusion polypeptide. Through CDR region humanized reconstruction and pH sensitive histidine switch design, the affinity of the matched antibody mAb SC-1 is improved by 5 times in a subacid environment, and the ADCC effect is enhanced through fucose-deficient host cells. Experiments show that when the fusion polypeptide is combined with the antibody, the senescent cell clearance rate can reach 45.2%, the collagen density is increased by 83.5%, and the effect is obviously superior to that of a single drug. The composition provided by the invention can be applied to the fields of cosmetics, medical instruments, medicines and functional foods, and provides a new strategy for treatment of senescence-related diseases and development of anti-senescence products.

Described herein are compositions for delaying onset or delaying progression of frailty, reversing aging phenotype, extending healthspan, compressing morbidity, increasing lifespan and reducing formation of senescent cells.

The present invention relates to a method, in particular an in vitro method, for identifying an improved anti-senescence compound based on detecting the binding of said compound in the presence of at least one phosphory lated amino acid in the transcription activation domain (TAD) domain of mammalian protein p53. The present invention further relates to a method, in particular an in vitro method, for monitoring an anti-senescence treatment or prophylaxis in a mammalian subject in need thereof, based on detecting the amount of phosphorylation of amino acids in the TAD and / or C-terminal region of the mammalian p53 protein in a biological sample obtained from said subject and / or detecting the amount and / or co-localization with phosphorylated p53 of the promyelocytic leukemia protein (PML) bodies in a biological sample obtained from said subject. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof. Finally, improved anti-senescence compounds or pharmaceutical compositions are provided.

The present invention discloses a photosensitizer prodrug compound (structural formula (I)) that selectively clears senescent cells and is specifically activated by the aging-associated β-galactosidase, as well as its preparation method and application. Upon activation by β-galactosidase, the compound rapidly releases its active molecule, anchoring it to proteins with nucleophilic groups. This allows for precise detection and covalent anchoring of senescent cells, thereby achieving selective clearance of senescent cells, reversing senescence-related markers and gene expression, and ameliorating aging-related decline in bodily functions. #imgabs0#

The invention discloses a preparation method of DRP1 engineered mitochondrial derived vesicles and application of the DRP1 engineered mitochondrial derived vesicles in cell aging resistance. The method comprises the following steps: firstly, constructing a lentiviral vector of an overexpressed DRP1 gene, and transfecting cells to obtain a cell strain of the stable overexpressed DRP1 gene; and culturing the cell strain, collecting a culture solution, and separating and extracting the mitochondrial derived vesicles to obtain the DRP1 engineered mitochondrial derived vesicles DRP1-MDVs rich in mtDNA. The DRP1-MDVs is used for treating senescent cells, the DRP1-MDVs is successfully internalized into senescent cells, the ROS level can be effectively reduced, the mitochondrial mtDNA and ATP content can be improved, the mtDNA mutation rate can be reduced, the mitochondrial membrane potential and the mitochondrial network structure can be recovered, and finally the expression of senescence-related proteins P16 and P21 can be reduced. The obvious mitochondrial function repairing potential and the cell aging improving effect are shown.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The present invention relates to the use of GRP78 and peptides similar thereto or nucleic acids encoding the same. The peptides or nucleic acids according to the present invention can increase the expression of biomarkers having reduced expression in senescent cells, and thus can be used to restore the function of muscle tissue that has decreased in function due to aging, etc.

The invention belongs to the technical field of biological medicines, and particularly relates to lipid nanoparticles as well as a preparation method and application thereof. The invention discloses a lipid nanoparticle. The material of the lipid nanoparticle comprises phospholipid and cholesterol. According to the invention, a lipid nano-carrier delivery system entrapped with apoptotic protein Bax is prepared through a microfluidic technology, and high encapsulation rate and stable delivery of protein drugs are realized. The nano-carrier delivery system capable of actively encapsulating the lipidosome realizes targeted delivery to senescent cells in vivo, so that senescent cell apoptosis is effectively induced, the proportion of senescent cells in tissues is reduced, and a new thought and means are provided for anti-aging treatment.

The application discloses a kind of composition with immunoregulation and anti-aging function and preparation method thereof, and core component is marine collagen peptide, fusion polypeptide CPF-1, targeting senescent cell monoclonal antibody mAb Senolix, five gallate acyl glucose (PGG) and Hericium erinaceus polysaccharide.Fusion polypeptide CPF-1 is designed by domain fusion strategy, with collagen binding, immune activation and antibacterial function;Monoclonal antibody mAb Senolix targets the surface antigen p16^(INK4a) of senescent cell, and removes senescent cell by ADCC effect.The composition significantly improves immune cell activity, promotes collagen synthesis and reduces chronic inflammation through the synergistic effect of multiple components, and shows excellent immunoregulation and anti-aging effect in in vitro cell model and immunosuppressed mouse model, and can be used for developing immune enhancer, anti-aging drug or functional food.

The invention relates to the technical field of daily cosmetics, in particular to a peony extract with scalp anti-aging and anti-hair-loss functions and application. The peony extract disclosed by the invention is a peony flower extract, the mass fraction of peony flower peptide in the peony flower extract is greater than or equal to 10%, and the peony extract disclosed by the invention is found to have the effects of improving the activity of superoxide dismutase (SOD) on human hair papilla cells for the first time; the positive cell rate of beta-galactosidase (SA-beta-Gal) of human hair papilla cells is inhibited, and the functions of senescent cells are reduced; meanwhile, the functions of promoting hair follicles to express growth factors and promoting hair growth are achieved. The method can be applied to preparation of scalp care products, and the anti-aging or anti-hair-loss function of scalp is achieved.

The application belongs to the technical field of functional polypeptides, and particularly relates to an active peptide for senescent cells and a preparation method thereof, wherein the active peptide is obtained by molecular docking simulation screening and optimization with a helical structure segment in an IL-6R protein combined with a gp130 protein as a polypeptide template; the active peptide after functional optimization contains an FF unit driving nano self-assembly, a GFLG unit capable of being specifically cut by a lysosome protease highly expressed in a microenvironment of senescent cells, and an RYFQKWEKLRNQ unit generating high affinity with an IL-6 / IL-6R / gp130 complex; the designed active peptide itself has anti-aging activity and can also be used for synergistic delivery of drugs, and has a broad application prospect.

It was discovered that by binding to CTCF which is important for maintaining chromosomal structures, hSATII RNA inhibits the function thereof, changes chromosome interaction, and induces transcription of inflammation-associated genes. It has also been discovered that cell death can be selectively induced in senescent cells and cancer cells by suppressing hSATII RNA expression. From the obtained results, it has been found that cancer treatment which targets senescent stromal cells and cancer cells can be performed with a substance that suppresses hSATII RNA or a substance that increases CTCF expression. In addition, cancer can be detected early by measuring the expression and activity of hSATII RNA and CTCF, and an epigenomic change of the hSATII DNA region. Thus, it is possible to provide a therapeutic drug for a cancer associated with cellular senescence, a method for screening thereof, and a test support method.

The present invention relates to a human pluripotent stem cell-derived senomorphic extracellular vesicle composition for treating cellular senescence and stem cell degeneration. Specifically, the present invention relates to a senomorphic composition comprising stem cell-derived extracellular vesicles as an active ingredient, the composition being characterized by restoring a function or morphology of senescent cells to that of normal cells, and to a pharmaceutical composition comprising the senomorphic composition as an active ingredient for preventing or treating nerve injury and ischemic diseases.

The technology relates in part to compositions containing a cell penetrating peptide that can be used to selectively reduce a senescent cell population. The technology also relates to methods of treatment of ageing and ageing-associated diseases using a cell penetrating peptide to selectively reduce a senescent cell population.

A method and apparatus for selecting microsecond pulsed electric field parameters for killing senescent cells. The method includes: 1) obtaining biological tissue cells and culturing them to obtain n groups of cell reagents containing normal cells and n groups of cell reagents containing senescent cells; 2) setting n groups of pulsed electric field parameters for killing senescent cells; 3) placing the i-th group of cell reagents containing normal cells and the i-th group of cell reagents containing senescent cells between an electrode pair, and electrically stimulating the i-th group of cell reagents containing normal cells and the i-th group of cell reagents containing senescent cells using the i-th group of pulsed electric field parameters; 4) performing cell activity detection, PI positivity rate detection, and electrosensitivity detection on each group of cell reagents after electrical stimulation to determine the optimal pulsed electric field parameters. The apparatus includes an electrode pair and a pulse generator. Compared with traditional treatment methods for chronic wounds, this invention only requires an electric field to efficiently and accurately kill senescent cells, without thermal effects or side effects.